Harold Burstein, Breast Cancer Specialist and Professor at Harvard Medical School and at Dana-Farber Cancer Institute, shared a post on X by Matthew Herper, Senior Writer of Medicine, and Editorial Director of Events at STAT, adding:
“Good to have a well-tolerated, oral SERD treatment option for patients with ESR1-mutated tumors.
Interesting that FDA did not approve the combo of imlunestrant/abema, which was active in the same trial, including in some patients without ESR1 mutated tumors.”
Quoting Matthew Herper’s post:
“U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer.”
More posts featuring Harold Burstein on OncoDaily.